39 results
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
. The study also evaluated numerous other endpoints, including bone mineral density (“BMD”) and annualized fracture rates, PK and safety. Across all
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
. This reduction was associated with improvements in bone mineral density (BMD). Setrusumab was well-tolerated with no serious adverse events or drug-related
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
with setrusumab reduced the annualized fracture rate by 67%. This reduction was associated with continuing large and meaningful improvements in bone mineral
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
with osteogenesis imperfecta (OI) with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral
6-K
MREO
Mereo Biopharma Group Plc
17 Oct 23
Current report (foreign)
7:01am
ongoing and meaningful improvements in lumbar spine bone mineral density (BMD).
As of the cut-off date and following at least 6 months of treatment
6-K
EX-99.1
btxendpgr
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.2
eh8eyzu aw6msd
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.3
8h3r3tck1u
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
n22x1uco
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
cegc 14wfe8y2y
7 Jun 23
Current report (foreign)
8:41am
6-K
EX-99.1
brhuv2fgva4 vt28u3
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
76rvbf5 m0h7k89x1oh
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
lxahmm
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
8edqxdp81urzmrg1 m5
2 Nov 21
Current report (foreign)
4:16pm
6-K
vho03a 0o
1 Oct 21
Current report (foreign)
4:43pm
6-K
EX-99.1
hwrrfzxxe45k2
1 Oct 21
Current report (foreign)
4:43pm
F-3/A
gwiqv4ijeuvompwawuv
27 Sep 21
Shelf registration (foreign) (amended)
4:18pm
F-3/A
gcxtbkwn8jtyjbz
7 Sep 21
Shelf registration (foreign) (amended)
4:06pm
F-3
fvghkwxzns 9xrw6ec
5 Aug 21
Shelf registration (foreign)
4:33pm